Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

MN-191 were accrued and payment to Roche was deferred. This $11.4 million payment will be made to Roche in 2009.

InterMune will make a scheduled Department of Justice (DOJ) payment of approximately $7.0 million in 2009. Additionally, the company anticipates that it may be required to make an accelerated payment to the DOJ of approximately $4.4 million related to the company's recent financing event. If both of these DOJ payments are made, the balance of the Liability Under Government Settlement would be approximately $13.2 million as of December 31, 2009.

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EST to discuss its financial results for the fourth quarter and full year 2008, and its forward-looking financial guidance. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 86755415. A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 86755415. The webcast will remain available on the company's website until the next earnings call.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Calif. (PRWEB) January 15, 2014 Cynvenio, ... and management through the genomic analysis of tumor cells ... Therapy Finder™, a web-based cancer decision support application powered ... option with Cynvenio’s ClearID™ genomic test, Therapy Finder will ...
(Date:1/15/2014)... A study has been launched to test ... track could help to tackle the problem of obesity.  This ... GP surgery based in Stowmarket) and academics at University Campus ... Telemetry technology, which is inspired by equipment used to collect ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to announce ... organizations who need document translations. Clients will now have ... in advance with a selection of nearly 50 life science ... critical factor in clinical and scientific fields, and decrease the ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Small Tree Communications , a supplier of high-performance networking ... software protocol called Blaze, expected to ship in the third ... High-Definition digital video editing. , ,Blaze will make it ... on the newer high-end 10 gigabit Ethernet cards. It ...
... Corporation and Middleton-based Bone Care International Inc. announced ... their proposed merger. , ,Genzyme and Bone Care have signed ... Care in an all-cash transaction valued at $33.00 per ... by Bone Care's shareholders at a meeting on ...
... - Stratatech Corp. was awarded a federal ... of General Medical Sciences to further develop its engineered human ... Madison and employs 18 people, according to the 2005 edition ... Its products are based on a source of pathogen-free human ...
Cached Biology Technology:Small Tree is streamlining digital video editing 2Small Tree is streamlining digital video editing 3
(Date:4/22/2014)... the University of Kentucky has discovered new methods to ... , The research, led by Peixuan Guo, professor and ... UK College of Pharmacy and Markey Cancer Center, is ... Anionic Polymer Material To Build Robust Structures with Defined ... Daniel L. Jasinski. , The article, which will appear ...
(Date:4/22/2014)... a trip to Asia to coordinate with allies ... officials at the Office of Naval Research (ONR) ... (APTEP) as an example of strong and growing ... in the region. , The APTEP program, centered ... supports the development of alternative energy technologies. It ...
(Date:4/22/2014)... is another way of asking him or her to ... Certain cells of the immune system tend to misbehave ... Because these cells are known to misbehave similarly during ... immune cells to better understand how our immune systems ... Institute on Aging, part of the National Institutes of ...
Breaking Biology News(10 mins):RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3For an immune cell, microgravity mimics aging 2For an immune cell, microgravity mimics aging 3For an immune cell, microgravity mimics aging 4For an immune cell, microgravity mimics aging 5
... who must stay awake for long shifts ?soldiers, pilots, ... from new research showing that preventing the gas nitric ... off the sleep urge. , The research, conducted by ... Helsinki (Helsinki, Finland), ties together previous observations about sleep ...
... scientists have engineered yeast cells capable of producing ... fully human sugar structures (glycosylation). These sugar structures ... to date, have necessitated the expression of therapeutic ... has the potential to eliminate the need for ...
... Emory University's Winship Cancer Institute have identified a novel ... role the marker may play when the tumor spreads ... is elevated in the cerebrospinal fluid of patients with ... in the November issue of Clinical Cancer Research. ...
Cached Biology News:Need to pull an all-nighter? 2GlycoFi and Dartmouth report full humanization of yeast glycosylation pathway in Science 2Newly identified biomarker detects and regulates spread of brain tumors 2
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
PGF1α-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGF1α by GC- or LC-mass spectrometry....
PGD2-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGD2 by GC- or LC-mass spectrometry....
Request Info...
Biology Products: